{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:24:48Z","timestamp":1791059088965,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Spinal muscular atrophy (SMA) is a neuromuscular disorder of childhood.<\/jats:p><jats:p>\u2022\u2003Riluzole is an anti\u2010excitatory agent recommended for the treatment of amyotrophic lateral sclerosis (ALS).<\/jats:p><jats:p>\u2022\u2003Riluzole pharmacokinetics are well documented in patients with ALS.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Riluzole pharmacokinetics have never documented in patients with SMA.<\/jats:p><jats:p>\u2022\u2003This study showed that the administration of 50\u2003mg riluzole once a day to patients with SMA leads to total riluzole daily exposure comparable with that obtained after the administration of 50\u2003mg twice a day in healthy volunteers or ALS patients.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold>The objective of the present study was to assess the pharmacokinetics of riluzole in patients with spinal muscular atrophy (SMA).<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold>Fourteen patients were enrolled in an open\u2010label, nonrandomized and repeat\u2010dose pharmacokinetic study. All participants were assigned to receive 50\u2003mg riluzole orally for 5 days. Riluzole plasma concentrations were determined from samples obtained at day 5.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>The pharmacokinetic analysis demonstrated that a dose of 50\u2003mg once a day was sufficient to obtain a daily total exposure [AUC(0,24\u2003h)\u2003=\u20032257\u2003ng\u2003ml<jats:sup>\u22121<\/jats:sup>\u2003h] which was comparable with results obtained in adult healthy volunteers or ALS patients in whom a dose of 50\u2003mg twice a day is recommended. The pharmacokinetic simulation demonstrated that the administration of 50\u2003mg twice a day could result in higher concentrations, hence reduced safety margin.<\/jats:p><jats:p><jats:bold>CONCLUSION<\/jats:bold>The dose of 50\u2003mg once a day was chosen for the clinical trial evaluating the efficacy of riluzole in SMA patients.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03843.x","type":"journal-article","created":{"date-parts":[[2010,11,7]],"date-time":"2010-11-07T10:54:30Z","timestamp":1289127270000},"page":"403-410","source":"Crossref","is-referenced-by-count":22,"title":["Riluzole pharmacokinetics in young patients with spinal muscular atrophy"],"prefix":"10.1111","volume":"71","author":[{"given":"Chadi","family":"Abbara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Estournet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucette","family":"Lacomblez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Leli\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Ouslimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Viollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Barois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Diquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000110905"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.12.1831"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(94)00090-V"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403033300901"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91680-3"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_4.233S"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb05630.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0022-3565(24)36944-7","article-title":"Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro","volume":"282","author":"Sanderink GJ","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10455"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.11.1601"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-3787(06)75039-1"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90047-3"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/009127009903900507","article-title":"A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers","volume":"39","author":"Le Liboux A","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000090459.76784.49"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100382"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0021"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121829"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04772.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.18433\/J36C78"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03843.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03843.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:14:15Z","timestamp":1740676455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03843.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03843.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03843.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}